{"id":"peg-rhgh-injection-semaglutide-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PEG-rhGH (pegylated recombinant human growth hormone) provides sustained growth hormone activity to enhance protein synthesis, lipolysis, and metabolic rate. Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, reduces glucagon, slows gastric emptying, and promotes satiety. Together, these agents target multiple metabolic pathways to address growth hormone deficiency while improving glycemic control and body composition.","oneSentence":"This combination therapy stimulates growth hormone secretion via PEG-rhGH while simultaneously activating GLP-1 receptors through semaglutide to promote metabolic effects and weight management.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:00:14.219Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency with concurrent metabolic dysfunction or obesity"},{"name":"Diabetes management in growth hormone-deficient patients"}]},"trialDetails":[{"nctId":"NCT06863363","phase":"PHASE4","title":"PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"","conditions":"Non-diabetic Obesity","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PEG-rhGH Injection + Semaglutide Injection","genericName":"PEG-rhGH Injection + Semaglutide Injection","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy stimulates growth hormone secretion via PEG-rhGH while simultaneously activating GLP-1 receptors through semaglutide to promote metabolic effects and weight management. Used for Growth hormone deficiency with concurrent metabolic dysfunction or obesity, Diabetes management in growth hormone-deficient patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}